Diversification strategiesIt’s a challenge that drugmakers are trying to address as they move to later-stage trials, when diversity is most key.
Early-stage trials are mainly intended to see if it’s safe enough to expand the test pool.Moderna is focusing on “sites with representative demography" and working with faith-based communities and employers for outreach help to recruit volunteers, a spokeswoman said.
Anthony Fauci, head of the NIAID, said Wednesday that it’s pre-enrolled a pool that’s 19% Black and 19% Latino.London-based AstraZeneca PLC, whose Phase I vaccine trial was 89% White, plans to focus on communities with high minority representation for recruiting test subjects.